J&J MedTech Unveils Promising 12-Month Data on Dual Energy Ablation Technology at EHRA 2025
Summary
Johnson & Johnson MedTech presented promising 12-month data at EHRA 2025 demonstrating the safety and effectiveness of its dual energy catheter, showing high success rates in atrial fibrillation treatment using both RF and pulsed field ablation.- Author Company: J&J MedTech
- Author Name: J&J MedTech
- Author Website: https://www.jnj.com/media-center
At the 2025 European Heart Rhythm Association (EHRA) Congress, Johnson & Johnson MedTech presented pivotal 12-month safety and effectiveness data from the SmartfIRE study—offering new insights into the future of atrial fibrillation (AFib) treatment. The data evaluated the THERMOCOOL SMARTTOUCH™ SF Dual Energy Catheter, a device that combines both radiofrequency (RF) and pulsed field (PF) energies within a single catheter platform.
The study, conducted across 10 European sites, demonstrated acute success in 100% of patients, with first-pass pulmonary vein isolation achieved in 96.8% of targeted veins. The dual energy approach, designed to enable physicians to tailor ablation strategies per patient, may support more efficient procedures and improved long-term outcomes.
“This unique study represents an important step forward in the development of dual energy ablation,” said Dr. Tom de Potter, primary investigator and associate director of the Cardiovascular Center Department of Cardiology at OLV Hospital in Aalst, Belgium. “The SmartfIRE study demonstrates that it is possible to safely and effectively combine pulsed field and radiofrequency energies in a single procedure, using a single catheter and mapping system.”
The device received CE mark approval earlier this year, and while it is not yet available in the United States, the results position it as a notable development in electrophysiology innovation.
Source: Johnson & Johnson MedTech Press Release, March 25, 2025
Read the original release
